Next Science_X Logo-02

Discover the X Factor in Wound Care

BlastX is an antimicrobial wound gel powered by Next Science’s patented, non-toxic Xbio technology. It deconstructs the bacterial biofilm EPS matrix, destroys bacteria within the gel, and defends from recolonization while maintaining a moist wound environment.

Others only address the tip of the iceberg.

See how the 3 Dimensions of BlastX
go deeper to solve the problem of
bacterial biofilm.


As opposed to planktonic bacteria, biofilms are powerful communities that function as a single entity with robust defense mechanisms. By targeting bacterial structures and breaking the ionic bonds that hold biofilm together, Next Science’s Xbio technology deconstructs the biofilm barrier without harming healthy human tissue.41


With the EPS matrix dissolved, bacteria are exposed and more vulnerable to attack. The Xbio technology creates a high osmolarity condition. This environment coupled with a surfactant induces cell lysis for bacteria enveloped within the gel. Cell lysis is nondiscriminatory, therefore Xbio destroys gram-positive and gram-negative bacteria, persister cells, and spores.41


Disrupting and destroying the biofilm barrier can reduce the rate of biofilm recurrence more than 100x, effectively defending against recolonization. While many other agents claim to destroy biofilms, there is no known evidence of bacterial resistance to the Xbio technology.41

BlastX Supersedes Current Therapy by Reducing Biofilm Bacteria 4-6 Log in Laboratory Tests

In in vitro studies, BlastX was compared to multiple current topical antimicrobial therapies. 24 hours after application, measurements were taken for two different kinds of biofilm bacteria (S. aureus and P. aeruginosa). Compared to the other topical antimicrobials, BlastX significantly reduced the number of biofilm bacteria present by 4 to 6 log.24, 41

U.S. Consensus Paper Highlights the Importance of Biofilm Disruption in Treating Chronic Wounds

BlastX Antimicrobial Wound Gel is featured in “Wound Biofilm: Current Perspectives on Biofilm Disruption and Treatments” in WOUNDS®, a compendium of clinical research and practice. The peer-reviewed paper provides a new perspective regarding the need for a paradigm shift toward biofilm treatment strategies and disruption of the bacterial biofilm protective matrix.


BlastX is indicated for the management of wounds such as Stage I-IV pressure ulcers, partial- and full-thickness wounds, diabetic foot and leg ulcers, post-surgical wounds, first and second degree burns, and grafted and donor sites.


BlastX is non-toxic and compatible with a broad range of advanced healing modalities that set the stage for better preparation and ongoing care of the wound bed.

Healthcare Provider Resources

For medical professionals working in the field of wound care or burn treatment, learn more about how Next Science BlastX can help your practice and your patients.